期刊文献+

骨髓增生异常综合征小分子药物靶点治疗的研究进展

下载PDF
导出
摘要 随着对骨髓增生异常综合征(MDS)发病机制的深入研究,小分子药物靶点治疗MDS已经取得了一定的进展。根除异常的细胞克隆和清除有利于MDS细胞生长的微环境是MDS治疗的主要目标。目前靶点治疗MDS的小分子药物主要有抗血管新生药物、法尼基转移酶抑制剂、格列卫、DNA甲基转移酶抑制剂、组蛋白去乙酰化酶抑制剂等。只有更深入地研究MDS的发病机制,才能使小分子药物靶点治疗 MDS取得更进一步的进展。
作者 薛志科 金洁
出处 《国外医学(输血及血液学分册)》 2005年第6期536-538,共3页 Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
  • 相关文献

参考文献20

  • 1List AF, Vardiman J, Issa JP, et al. Myelodysplastic syndromes.Hematology (Am Soc Hematol Educ Program),2004,297-317.
  • 2Mufti G, List AF, Gore SD, et al. Myelodysplastic syndromes.Hematology (Am Soc Hematol Educ Program),2003,176-199.
  • 3Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001,98 (4):958-965.
  • 4Moreno-Aspitia A, Geyer S, Li C, et al. N998B: multicenter phase Ⅱ trial of thalidomide (Thai) in adult patients with myelodysplastic syndromes (MDS). Blood ,2002,100 (11 ) : 96.
  • 5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood ,2001,98(1) :210-216.
  • 6Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia ormyelodysplastic syndromes. Blood,2003,102(11):795-801.
  • 7Albitar M, Smolich BD, Cherrington JM, et al. Effects of SU5416 on angiogenic factors, proliferation and apoptosis in patients with hematological malignancies. Blood, 2001,98 ( 11 ) : 110.
  • 8List AF, Schiller GJ, Mason J, et al. Trisenox (arsenic trioxide)in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase Ⅱ clinical study. Blood,2003,102 (2):423.
  • 9Raza A, Lisak LA, Tahir S, et al. Trilineage responses to arsenic trioxide ( Trisenox ) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3) (q21q26.2). Blood ,2002,100(11) :795.
  • 10Vey N, Dreyfus F, Guerci A, et al. Trisenox? (arsenic trioxide) in patients (pts) with myelodysplastic syndromes ( MDS ):Preliminary results of a phase 1/2 study, the 8th Congress of the European Hematology Association, Lyon, France, 2003,12-15.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部